Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir
- 1 August 1999
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 21 (5), 371
- https://doi.org/10.1097/00042560-199908150-00003
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Detection of HIV Type 1envSubtypes A, B, C, and E in Asia Using Dried Blood Spots: A New Surveillance Tool for Molecular EpidemiologyAIDS Research and Human Retroviruses, 1996
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Quantifying HIV-1 RNA Using the Polymerase Chain Reaction on Cerebrospinal Fluid and Serum of Seropositive Individuals With and Without Neurologic AbnormalitiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- Study on didanosine concentrations in cerebrospinal fluidInternational Journal of Clinical Pharmacy, 1995
- Detection Of Drug Resistance Mutations In The Human Immunodeficiency Virus Type I (HIV-I) pol Gene: Differences In Semen And Blood HIV-I RNA And Proviral DNAThe Journal of Infectious Diseases, 1994
- Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trialAnnals of Neurology, 1993
- Neuropsychological Outcome of Zidovudine (AZT) Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1988